WuXi Apptec WKN: A2PAJG ISIN: CNE100003F19 Kürzel: WX8 Forum: Aktien User: Summer.76

Citi: First to WuXi AppTec (02359) with a target price of HK$236, rating "Buy" https://finance.sina.cn/hkstock/ggyw/2021-01-20/detail-ikftpnnx9695874.d.html?from=wap Citi released a research report that China's pharmaceutical R&D outsourcing and production outsourcing (CRO/CDMO) companies have relatively good cost efficiency and a growing talent pool, and are the first to give the next four companies a "buy" rating.   ... Citi stated that the cost of Chinese pharmaceutical outsourcing companies is 30%-60% lower than that of manufacturers in developed countries. CRO/CDMO companies in China are less affected by public health incidents. According to data from consulting firm Frost & Sullivan, the Chinese R&D outsourcing market The scale in 2019 is US$6.9 billion, and it is expected to reach US$16.9 billion in 2023. The above four companies are the leaders in their fields, and the compound annual growth rate of profit in 2019-2023 is expected to be between 24%-40%.

http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02359/NOW.1070604/hk-stock-news Citi initiates WUXI APPTEC at Buy with TP $236